Effect of Eplerenone on Endothelial Function in Patients With Stable Coronary Heart Disease
NCT ID: NCT00427284
Last Updated: 2011-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
42 participants
OBSERVATIONAL
2004-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Additionally we hypothesize that selective aldosterone antagonism reduces systemic inflammatory response such as C-reactive proteine, oxidative stress and pro-inflammatory cytokines.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stable cardiovascular medication for at least 4 months Evaluation of the patients will take place at the Department of Internal Medicine, Cardiology, University Hospital Zurich.
Exclusion Criteria
* coronary intervention/re-vascularisation procedure within 3 months prior to study entry
* long acting nitrates
* uncontrolled arterial hypertension, defined as RR\>160/90 mmHg
* congestive heart failure (\> NYHA I)
* Ejection fraction \<50%
* AV-Block\>I˚
* creatinine clearance \<50 mL/min
* insulin-dependent diabetes mellitus
* type 2 diabetes with microalbuminuria
* age \< 30 years
* anemia (Hb\<10 g/dl)
* malignancy chronic infection
* smoking
* serum potassium \>5.5 meq/L
* drug abuse
* potassium supplements or potassium-sparing diuretics (amiloride, spironolactone, or triamterene)
* concomitant use of strong inhibitors of CYP450 3A4 (e.g., ketoconazole, itraconazole)
* known history of Cushing disease or Morbus Addisons or diseases of the thyroid gland
30 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Zurich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Frank Ruschitzka, Prof MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital Zurich, Division of Cardiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Zurich, Division of Cardiology
Zurich, Canton of Zurich, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EK 1033
Identifier Type: -
Identifier Source: org_study_id